C-kit is important for SOD1G93A mouse survival independent of mast cells

[1]  S. Bates,et al.  Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosis. , 2014, Human molecular genetics.

[2]  A. Goris,et al.  EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans , 2012, Nature Medicine.

[3]  V. Meininger,et al.  Elevated levels of IFNγ and LIGHT in the spinal cord of patients with sporadic amyotrophic lateral sclerosis , 2012, European journal of neurology.

[4]  E. Beghi,et al.  Incidence of amyotrophic lateral sclerosis in Europe , 2009, Journal of Neurology, Neurosurgery & Psychiatry.

[5]  P. Vergara,et al.  Mast Cell Stabilizer Ketotifen [4-(1-Methyl-4-piperidylidene)-4H-benzo[4,5]cyclohepta[1,2-b]thiophen-10(9H)-one Fumarate] Prevents Mucosal Mast Cell Hyperplasia and Intestinal Dysmotility in Experimental Trichinella spiralis Inflammation in the Rat , 2006, Journal of Pharmacology and Experimental Therapeutics.

[6]  Jean-Pierre Julien,et al.  Transgenic mouse models of amyotrophic lateral sclerosis. , 2006, Biochimica et biophysica acta.

[7]  S. Niclou,et al.  The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease , 2006, Molecular and Cellular Neuroscience.

[8]  D. Gozal,et al.  Motor Neuron Degeneration Promotes Neural Progenitor Cell Proliferation, Migration, and Neurogenesis in the Spinal Cords of Amyotrophic Lateral Sclerosis Mice , 2006, Stem cells.

[9]  K. Ishii,et al.  Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. , 2006, British journal of clinical pharmacology.